Breast Cancer: EA1131 (Iowa Cancer Specialists)

EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Objective

The purpose of this study is to compare getting more treatment with capecitabine (i.e. one of the usual approaches), to any good and bad effects of getting more treatment with a platinum-based chemotherapy (cisplatin or carboplatin), after surgery for patients with triple-negative breast cancer. 

Patients that are eligible for this study include:

  1. Patients that have breast cancer that does not have the estrogen, progesterone or HER2 receptor, which is called triple-negative breast cancer
  2. Patients that have completed all chemotherapy prior to surgery
  3. Patients that had greater than or equal to 1 cm worth of cancer in the breast at the time of surgery
  4. Patient that have completed radiation treatment after surgery, if indicated
Principal Investigator(s)
George Kovach

Clinical Trial Categories

  • Breast Cancer
Sponsor(s)
Eastern Cooperative Oncology Group
Contact
Kim Turner, R.N. at 563-421-1908
or turnerk@genesishealth.com

Location

  • Medical Center, West Central Park
    1401 West Central Park
    Davenport, IA 52804
    Main: 563-421-1000

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email